Leptomeningeal melanomatosis with multiple cutaneous pigmented nevi: Tumor cell proliferation and malignant transformation in an autopsy case

Journal of Neuro-Oncology

Volumn 44, Issue 1, 1999, Pages 41-45

  Oka, Hidehiro ^a   Kameya, Toru ^a   Hata, Takashi ^a   Kawano, Nobuyuki ^a   Fujii, Kiyotaka ^a   Yada, Kenzo ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Melanoma; Melanomatosis; p53; Prognosis; Proliferation

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; AUTOPSY; BRAIN; CANCER INVASION; CASE REPORT; CELL NUCLEUS; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEPTOMENINX; MALE; MALIGNANT TRANSFORMATION; MELANOMA; MELANOSIS; PARENCHYMA; PIGMENTED NEVUS; SUBARACHNOID SPACE; TUMOR CELL;

ADULT; AUTOPSY; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; NEVUS, PIGMENTED; SKIN NEOPLASMS;

EID: 0032743337     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006127619926     Document Type: Article

References (26)

1. Kadonaga JN, Frieden IJ: Neurocutaneous melanosis: Definition and review of the literature. J Am Acad Dermatol 24: 747-755, 1991
2. Rokitansky J: Ein ausgezeichneter Fall von Pigmentmal mit ausgebreiter Pigmentierung der inneren hirn- und Ruckenmarkshaut. Allg Wien Med Z 6: 113-116, 1861
3. Virchow R: Pigment und diffuse Melanose der Arachnoides. Virchows Archiv 16: 180-182, 1859
4. DeDavid M, Orlow SJ, Provost N, Marghoob AA, Roa BK, Wasti Q, Huang CL, Kopf AW, Bart RS: Neurocutaneous melanosis: Clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol 35: 529-538, 1996
5. Savitz MH, Anderson PJ: Primary melanoma of the leptomeninges: A review. Mount Sinai J Med 41: 774-791, 1974
6. Gown AM, Vogel AM, Hoak D, Gouh F, McNutt MA: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123: 195-203, 1986
7. Key G, Becker MH, Baron B, Duchrow M, Schluter C, Flad HD, Gerdes J: New Ki-67-equivalent marine monoclonal antibodies (MIB-1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68: 629-636, 1993
8. Vanden Berg FM, Baas IO, Polak MM, Offenhaus GJA: Detection of p53 overexpression in routinaly paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol 142: 381-385, 1993
9. Sato Y, Nakajima T, Kuroki M, Abe Y, Watanabe S: Examination of the unlabelled antibody enzyme (PAP) method. Rinsho-Kensa 25: 449-453, 1981 (in Japanese)
10. Russel DS, Rubinstein LJ: Pathology of tumors of the Nervous system. 5th ed.,Williams and Wilkins, Baltimore, 1989, 792 pp
11. Fuller GN, Burger PC: Central nervous system. In: Stemberg SS (ed) Histology for Pathologists. Raven Press, New York, 1992, pp 145-167.
12. Lewis MG: Melanoma and pigmentation of the leptomeninges in Ugandan Africans. J Clin Pathol 22: 183-186, 1969
13. Quaba AA, Wallace AF: The incidence of malignant melanoma (0 to 15 years of age) arising in 'large' congenital nevocellular nevi. Plast Reconstr Surg 78: 174-179, 1986
14. Ruiz-Maldonado R, Tamayo L, Laterzo AM, Duran C: Giant pigmented nevi: Clinical, histopathologic, and therapeutic considerations. J Pediatr 120: 906-911, 1992
15. Slaughter JC, Hardman JM, Kempe LG, Earle KM: Neurocutaneous melanosis and leptomeningeal melanomatosis in children. Arch Pathol 88: 298-304, 1969
16. Boni R, Doguoglu A, Burg G, Muller B, Dummer R: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 35: 416-418, 1996
17. Ramsay JA, From L, Iscoe NA, Kahn HJ: MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 105: 22-26, 1995
18. Berger DP, Herbstritt L, Dengler WA, Marme D, Mertelsmann R, Fiebig HH: Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 6: 817-825, 1995
19. Halaban R: Growth factors and melanomas. Seminars in Oncology 23: 673-681, 1996
20. Lubbe J, Reichel M, Burg G, Kleihues P: Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 102: 819-821, 1994
21. Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhorn-Dworniczak B: Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 7: 331-339, 1995
22. Saenz-Santamaria MC, McNutt NS, Bogdany JK, Shea CR: p53 expression is rare in cutaneous melanomas. Am J Dermatol 17: 344-349, 1995
23. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang Z-F, Rosai J, Reuter VE, Pellicer A: p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 56: 347-353, 1994
24. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RT: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397, 1993
25. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142: 1534-1543, 1993
26. Kennedy SM, MacGeogh C, Jaffe R, Spurr NK: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25: 438-442, 1994